What is the Suven Life Sciences Ltd share price today?

The share price of NSE:SUVEN-EQ on 01 Oct 2026 (as of 15:05:01 IST) is ₹307.45.

What is the NSE:SUVEN-EQ 52 week high low price?

Over the past 52 weeks (as of 01 Oct 2026), the NSE:SUVEN-EQ 52 week high low range shows a high of ₹403.35 and a low of ₹124.11.

What is the Suven Life Sciences Ltd market cap?

As on 01 Oct 2026, Suven Life Sciences Ltd market cap is ₹90420100000.

What is the shareholding pattern of Suven Life Sciences Ltd Stock?

The shareholding pattern of Suven Life Sciences Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 70.08% Foreign Institutional Investors (FII): 0.56% Domestic Institutional Investors (DII): 2.92% Mutual Funds: 0.01% Retail & Others: 26.43% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of Suven Life Sciences Ltd?

The Price-to-Earnings (PE) ratio of Suven Life Sciences Ltd is 0, and the Price-to-Book (PB) ratio is 8.0694, as on 01 Oct 2026.

Suven Life Sciences Share Price

261.60+0.40 (+0.15%)

+27.78% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

1 Day

+0.15%

1 Week

+1.06%

1 Month

-14.59%

3 Month

-17.68%

6 Month

+17.32%

YTD

+57.33%

1 Year

+27.78%

5 Year

+182.84%

10 Year

+53.60%

Max

+1583.67%

YTD

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

261.20

256.30

202.31

124.11

High

261.20

275.50

316.90

403.35

About

Suven Life Sciences provides wide range of Drug Discovery and Development Support Services (DDDSS) to global Pharma and Biotech companies. Suven has state-of-art facilities with highly qualified & experienced team Read more

Pharmaceuticals & Drugs

Smallcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

SUNPHARMANSE

DIVISLABNSE

TORNTPHARMNSE

LAURUSLABSNSE

ZYDUSLIFENSE

DRREDDYNSE

CIPLANSE

MANKINDNSE

AUROPHARMANSE

LUPINNSE

SUVENNSE

LTP

1W Low

1W High

Market cap (₹)

1769.9-7.8 (-0.44%)

1722

1855

4,24,202Cr

10064+284 (2.90%)

9621.50

10064

2,64,141Cr

4650+36.6 (0.79%)

4532

4675

1,74,402Cr

2323-82.5 (-3.43%)

2206.10

2441.90

1,26,811Cr

1240.6-4.9 (-0.39%)

1182

1254.20

1,23,685Cr

1368.3+16.3 (1.21%)

1336.70

1368.30

1,11,868Cr

1396.9+18 (1.31%)

1357

1396.90

1,11,650Cr

2475-17.8 (-0.71%)

2457.90

2528

1,02,196Cr

1694.5+13.1 (0.78%)

1647.20

1697.40

96,951Cr

2015.9+4.9 (0.24%)

1974

2033.80

91,301Cr

261.2+2.35 (0.91%)

256.30

275.50

7,679Cr

Suven Life Sciences Share Price

261.60+0.40 (+0.15%)

+27.78% past 1 Year

Open a free Demat account in minutes to start investing and screening .

Suven Life Sciences Share Price

261.60+0.40 (+0.15%)

+27.78% past 1 Year

Financial overview

Compounded Sales Growth

10 years-35%

5 years-12%

3 years-19%

Last year7%

Compounded Profit Growth

10 years-

5 years-

3 years-

Last year-72%

Stock Price CAGR

10 years4%

5 years23%

3 years50%

1 year28%

Return on Equity

10 years-51%

5 years-83%

3 years-73%

Last year-102%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
-35%	-12%	-19%	7%
-	-	-	-72%
4%	23%	50%	28%
-51%	-83%	-73%	-102%

Peer Comparison

Symbol

SUNPHARMA

DIVISLAB

TORNTPHARM

LAURUSLABS

ZYDUSLIFE

DRREDDY

CIPLA

MANKIND

AUROPHARMA

LUPIN

SUVEN

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
1,769.9	₹424202 Cr	38.68	8.29	58.23	₹11479 Cr
10,064	₹264141 Cr	90.3	34.04	128.41	₹2568 Cr
4,650	₹174402 Cr	82.11	14.04	106.21	₹2163 Cr
2,323	₹126811 Cr	94.64	8.17	33.94	₹889 Cr
1,240.6	₹123685 Cr	27.41	9.42	62.53	₹5040 Cr
1,368.3	₹111868 Cr	39.95	11.08	59.2	₹4196 Cr
1,396.9	₹111650 Cr	38.54	10.86	52.6	₹3879 Cr
2,475	₹102196 Cr	45.57	17.23	76.26	₹1913 Cr
1,694.5	₹96951 Cr	26.11	17.95	96.84	₹3505 Cr
2,015.9	₹91301 Cr	16.51	30.95	154.35	₹5333 Cr
261.2	₹7679 Cr	—	-4.83	-12.25	-₹276 Cr

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

Name

Net Revenue

Other Income

Total Revenue

Total Expenditure

Operating Profit

Interest Expense

PBT

Net Profit

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022	Dec 2021	Sep 2021	Jun 2021	Mar 2021	Dec 2020	Sep 2020	Jun 2020	Mar 2020	Dec 2019	Sep 2019	Jun 2019	Mar 2019	Dec 2018	Sep 2018	Jun 2018
₹4 Cr	₹2 Cr	₹3 Cr	₹92 L	₹2 Cr	₹1 Cr	₹2 Cr	₹3 Cr	₹1 Cr	₹2 Cr	₹2 Cr	₹3 Cr	₹4 Cr	₹3 Cr	₹3 Cr	₹4 Cr	₹4 Cr	₹4 Cr	₹4 Cr	₹1 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹9 Cr	₹1 Cr	₹9 Cr	₹3 Cr	₹274 Cr	₹199 Cr	₹253 Cr	₹2 Cr	₹90 Cr	₹192 Cr
₹8 Cr	₹7 Cr	₹3 Cr	₹4 Cr	₹60 L	₹1 Cr	₹2 Cr	₹4 Cr	₹4 Cr	₹4 Cr	₹6 Cr	₹5 Cr	₹6 Cr	₹6 Cr	₹2 Cr	₹21 L	₹44 L	₹12 L	₹14 L	₹50 L	₹84 L	₹1 Cr	₹2 Cr	₹2 Cr	₹3 Cr	₹3 Cr	₹6 Cr	₹6 Cr	₹3 Cr	₹4 Cr	₹7 Cr	₹7 Cr	₹8 Cr
₹11 Cr	₹8 Cr	₹6 Cr	₹5 Cr	₹2 Cr	₹3 Cr	₹3 Cr	₹7 Cr	₹5 Cr	₹7 Cr	₹9 Cr	₹8 Cr	₹9 Cr	₹8 Cr	₹5 Cr	₹5 Cr	₹4 Cr	₹4 Cr	₹5 Cr	₹2 Cr	₹3 Cr	₹3 Cr	₹3 Cr	₹11 Cr	₹4 Cr	₹12 Cr	₹9 Cr	₹280 Cr	₹202 Cr	₹257 Cr	₹9 Cr	₹96 Cr	₹200 Cr
₹138 Cr	₹54 Cr	₹108 Cr	₹82 Cr	₹54 Cr	₹47 Cr	₹42 Cr	₹56 Cr	₹33 Cr	₹34 Cr	₹50 Cr	₹28 Cr	₹33 Cr	₹36 Cr	₹56 Cr	₹28 Cr	₹26 Cr	₹25 Cr	₹38 Cr	₹30 Cr	₹46 Cr	₹24 Cr	₹29 Cr	₹28 Cr	₹17 Cr	₹35 Cr	₹31 Cr	₹178 Cr	₹145 Cr	₹184 Cr	₹23 Cr	₹85 Cr	₹152 Cr
-₹125 Cr	-₹44 Cr	-₹101 Cr	-₹76 Cr	-₹50 Cr	-₹43 Cr	-₹38 Cr	-₹48 Cr	-₹27 Cr	-₹26 Cr	-₹40 Cr	-₹18 Cr	-₹22 Cr	-₹26 Cr	-₹49 Cr	-₹21 Cr	-₹21 Cr	-₹20 Cr	-₹32 Cr	-₹27 Cr	-₹42 Cr	-₹20 Cr	-₹25 Cr	-₹15 Cr	-₹12 Cr	-₹22 Cr	-₹22 Cr	₹108 Cr	₹62 Cr	₹79 Cr	-₹13 Cr	₹17 Cr	₹54 Cr
₹48 L	₹16 L	₹0	₹0	₹0	₹0	₹80,000	₹2 L	₹2 L	₹3 L	₹4 L	₹4 L	₹5 L	₹5 L	₹6 L	₹7 L	₹10 L	₹10 L	₹13 L	₹15 L	₹15 L	₹24 L	₹18 L	₹26 L	₹22 L	₹23 L	₹10 L	₹2 Cr	₹2 Cr	₹2 Cr	₹0	₹59 L	₹1 Cr
-₹128 Cr	-₹46 Cr	-₹102 Cr	-₹77 Cr	-₹52 Cr	-₹44 Cr	-₹39 Cr	-₹50 Cr	-₹28 Cr	-₹28 Cr	-₹42 Cr	-₹13 Cr	-₹24 Cr	-₹28 Cr	-₹51 Cr	-₹23 Cr	-₹16 Cr	-₹21 Cr	-₹34 Cr	-₹28 Cr	-₹39 Cr	-₹22 Cr	-₹26 Cr	-₹17 Cr	-₹13 Cr	-₹23 Cr	-₹23 Cr	₹100 Cr	₹55 Cr	₹72 Cr	-₹14 Cr	₹11 Cr	₹47 Cr
-₹128 Cr	-₹46 Cr	-₹102 Cr	-₹77 Cr	-₹52 Cr	-₹44 Cr	-₹39 Cr	-₹50 Cr	-₹28 Cr	-₹27 Cr	-₹42 Cr	-₹13 Cr	-₹24 Cr	-₹28 Cr	-₹51 Cr	-₹23 Cr	-₹16 Cr	-₹21 Cr	-₹34 Cr	-₹28 Cr	-₹39 Cr	-₹22 Cr	-₹24 Cr	-₹16 Cr	-₹10 Cr	-₹26 Cr	-₹23 Cr	₹63 Cr	₹26 Cr	₹38 Cr	-₹14 Cr	₹4 Cr	₹26 Cr

Balance Sheet

Consolidated

Standalone

₹

Name

Equity And Liabilities

Share Capital

Share Warrants & Outstandings

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Secured Loans

Unsecured Loans

Deferred Tax Assets / Liabilities

Other Long Term Liabilities

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Current Liabilities

Total Liabilities

Contingent Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Net Block

Capital Work in Progress

Non Current Investments

Long Term Investment

Long Term Loans & Advances

Other Non Current Assets

Total Non-Current Assets

Current Assets Loans & Advances

Currents Investments

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Miscellaneous Expenses not written off

Total Assets

Book Value

Adjusted Book Value

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2008	Mar 2007	Mar 2006	Mar 2005	Mar 2004
—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
₹26 Cr	₹22 Cr	₹22 Cr	₹22 Cr	₹15 Cr	₹13 Cr	₹13 Cr	₹13 Cr	₹13 Cr	₹13 Cr	₹13 Cr	₹13 Cr	₹12 Cr	₹6 Cr	₹5 Cr	₹5 Cr	₹5 Cr
₹157 Cr	₹1 Cr	₹0	₹0	₹0	₹37 Cr	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0
₹408 Cr	₹87 Cr	₹248 Cr	₹354 Cr	₹82 Cr	₹58 Cr	₹131 Cr	₹226 Cr	₹755 Cr	₹654 Cr	₹583 Cr	₹547 Cr	₹95 Cr	₹96 Cr	₹85 Cr	₹76 Cr	₹77 Cr
₹408 Cr	₹87 Cr	₹248 Cr	₹354 Cr	₹82 Cr	₹58 Cr	₹131 Cr	₹226 Cr	₹755 Cr	₹654 Cr	₹583 Cr	₹547 Cr	₹95 Cr	₹96 Cr	₹85 Cr	₹76 Cr	₹77 Cr
₹591 Cr	₹110 Cr	₹270 Cr	₹375 Cr	₹96 Cr	₹108 Cr	₹143 Cr	₹239 Cr	₹767 Cr	₹667 Cr	₹595 Cr	₹559 Cr	₹106 Cr	₹102 Cr	₹90 Cr	₹81 Cr	₹82 Cr
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹25 L	₹23 Cr	₹38 Cr	₹55 Cr	₹55 Cr	₹41 Cr	₹24 Cr	₹20 Cr	₹21 Cr
₹0	₹0	₹0	₹0	₹0	₹39 L	₹1 Cr	₹2 Cr	₹2 Cr	₹3 Cr	₹4 Cr	₹6 Cr	₹0	₹0	₹0	₹0	₹0
₹0	₹0	₹0	₹0	₹0	₹0	₹6 Cr	₹20 Cr	₹23 Cr	-₹2 Cr	-₹5 Cr	₹23 Cr	₹2 Cr	₹5 Cr	₹7 Cr	₹13 Cr	₹10 Cr
₹12 Cr	₹0	₹0	₹58 L	₹2 Cr	₹2 Cr	₹3 Cr	₹76 L	₹1 Cr	₹1 Cr	₹1 Cr	₹0	₹0	₹0	₹0	₹0	₹0
₹2 Cr	₹2 Cr	₹1 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹1 Cr	₹4 Cr	₹3 Cr	₹2 Cr	₹2 Cr	₹0	₹0	₹0	₹0	₹0
₹14 Cr	₹2 Cr	₹1 Cr	₹2 Cr	₹4 Cr	₹5 Cr	₹12 Cr	₹25 Cr	₹30 Cr	₹28 Cr	₹41 Cr	₹86 Cr	₹57 Cr	₹47 Cr	₹31 Cr	₹33 Cr	₹31 Cr
—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
₹5 Cr	₹5 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹3 Cr	₹6 Cr	₹7 Cr	₹57 Cr	₹38 Cr	₹36 Cr	₹44 Cr	₹20 Cr	₹12 Cr	₹12 Cr	₹12 Cr	₹7 Cr
₹12 Cr	₹17 Cr	₹10 Cr	₹8 Cr	₹5 Cr	₹12 Cr	₹20 Cr	₹32 Cr	₹29 Cr	₹46 Cr	₹48 Cr	₹42 Cr	₹63 L	₹1 Cr	₹29 L	₹27 L	₹21 L
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹31 Cr	₹30 Cr	₹24 Cr	₹28 Cr	₹0	₹0	₹0	₹0	₹0
₹2 Cr	₹2 Cr	₹1 Cr	₹95 Cr	₹95 Cr	₹95 Cr	₹94 Cr	₹118 Cr	₹109 Cr	₹93 Cr	₹103 Cr	₹13 Cr	₹14 Cr	₹12 Cr	₹10 Cr	₹9 Cr	₹9 Cr
₹19 Cr	₹23 Cr	₹14 Cr	₹105 Cr	₹102 Cr	₹110 Cr	₹120 Cr	₹157 Cr	₹226 Cr	₹208 Cr	₹211 Cr	₹127 Cr	₹35 Cr	₹25 Cr	₹22 Cr	₹22 Cr	₹16 Cr
₹624 Cr	₹135 Cr	₹285 Cr	₹483 Cr	₹202 Cr	₹222 Cr	₹275 Cr	₹421 Cr	₹1023 Cr	₹903 Cr	₹846 Cr	₹773 Cr	₹199 Cr	₹173 Cr	₹143 Cr	₹136 Cr	₹129 Cr
₹6 Cr	₹6 Cr	₹4 Cr	₹0	₹0	₹0	₹0	₹8 L	₹10 Cr	₹9 Cr	₹7 Cr	₹12 Cr	₹7 Cr	₹4 Cr	₹3 Cr	₹6 Cr	₹3 Cr
₹0	₹0	₹0	₹0	₹48 L	₹1 Cr	₹2 Cr	₹3 Cr	₹34 Cr	₹71 Cr	₹83 Cr	₹109 Cr	₹55 Cr	₹41 Cr	₹24 Cr	₹20 Cr	₹21 Cr
—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
₹130 Cr	₹113 Cr	₹78 Cr	₹88 Cr	₹83 Cr	₹67 Cr	₹77 Cr	₹39 Cr	₹376 Cr	₹349 Cr	₹325 Cr	₹291 Cr	₹141 Cr	₹120 Cr	₹102 Cr	₹89 Cr	₹78 Cr
₹57 Cr	₹53 Cr	₹50 Cr	₹51 Cr	₹46 Cr	₹46 Cr	₹52 Cr	₹17 Cr	₹68 Cr	₹43 Cr	₹20 Cr	₹119 Cr	₹31 Cr	₹25 Cr	₹19 Cr	₹14 Cr	₹10 Cr
₹73 Cr	₹60 Cr	₹28 Cr	₹37 Cr	₹38 Cr	₹21 Cr	₹25 Cr	₹22 Cr	₹308 Cr	₹306 Cr	₹305 Cr	₹172 Cr	₹110 Cr	₹96 Cr	₹83 Cr	₹74 Cr	₹67 Cr
₹4 Cr	₹97,000	₹0	₹0	₹4 Cr	₹5 Cr	₹0	₹2 L	₹25 Cr	₹10 Cr	₹7 Cr	₹107 Cr	₹4 Cr	₹5 Cr	₹3 Cr	₹3 Cr	₹1 Cr
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹7 L	₹7 L	₹7 L	₹0	₹2 Cr	₹5 Cr	₹4 Cr	₹7 Cr	₹15 Cr
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹7 L	₹7 L	₹7 L	₹0	₹2 Cr	₹5 Cr	₹4 Cr	₹7 Cr	₹15 Cr
₹91 L	₹5 L	₹2 L	₹11 L	₹33 L	₹0	₹91 Cr	₹0	₹17 Cr	₹6 Cr	₹6 Cr	₹11 Cr	₹0	₹0	₹0	₹0	₹0
₹0	₹0	₹0	₹100 Cr	₹0	₹0	₹0	₹0	₹20 L	₹20 L	₹0	₹1 Cr	₹0	₹0	₹0	₹0	₹0
₹78 Cr	₹60 Cr	₹28 Cr	₹137 Cr	₹41 Cr	₹26 Cr	₹116 Cr	₹22 Cr	₹350 Cr	₹322 Cr	₹319 Cr	₹291 Cr	₹116 Cr	₹106 Cr	₹90 Cr	₹85 Cr	₹84 Cr
—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
₹181 Cr	₹22 Cr	₹76 Cr	₹46 Cr	₹45 Cr	₹9 L	₹5 L	₹223 Cr	₹279 Cr	₹301 Cr	₹5 L	₹4 L	₹0	₹0	₹0	₹0	₹0
₹10 L	₹24 L	₹71 L	₹0	₹2 L	₹14 L	₹0	₹0	₹139 Cr	₹93 Cr	₹83 Cr	₹82 Cr	₹24 Cr	₹23 Cr	₹23 Cr	₹19 Cr	₹12 Cr
₹2 Cr	₹1 Cr	₹1 Cr	₹81 L	₹1 Cr	₹2 Cr	₹2 Cr	₹3 Cr	₹62 Cr	₹46 Cr	₹54 Cr	₹40 Cr	₹36 Cr	₹16 Cr	₹15 Cr	₹19 Cr	₹11 Cr
₹337 Cr	₹38 Cr	₹164 Cr	₹184 Cr	₹6 Cr	₹47 Cr	₹15 Cr	₹69 L	₹28 Cr	₹9 Cr	₹241 Cr	₹280 Cr	₹3 Cr	₹10 Cr	₹1 Cr	₹3 Cr	₹12 Cr
₹5 Cr	₹1 Cr	₹3 Cr	₹5 Cr	₹1 Cr	₹3 Cr	₹35 L	₹20 L	₹14 Cr	₹8 Cr	₹3 Cr	₹41 Cr	₹5 Cr	₹4 Cr	₹5 Cr	₹2 Cr	₹2 Cr
₹22 Cr	₹13 Cr	₹12 Cr	₹109 Cr	₹107 Cr	₹145 Cr	₹142 Cr	₹172 Cr	₹151 Cr	₹125 Cr	₹146 Cr	₹34 Cr	₹15 Cr	₹14 Cr	₹10 Cr	₹9 Cr	₹8 Cr
₹547 Cr	₹75 Cr	₹257 Cr	₹345 Cr	₹160 Cr	₹197 Cr	₹160 Cr	₹398 Cr	₹674 Cr	₹581 Cr	₹528 Cr	₹477 Cr	₹83 Cr	₹68 Cr	₹53 Cr	₹51 Cr	₹45 Cr
₹528 Cr	₹52 Cr	₹243 Cr	₹240 Cr	₹58 Cr	₹87 Cr	₹39 Cr	₹241 Cr	₹448 Cr	₹373 Cr	₹317 Cr	₹350 Cr	₹48 Cr	₹43 Cr	₹31 Cr	₹30 Cr	₹29 Cr
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹5 Cr	₹2 L	₹4 L	₹6 L	₹9 L	₹11 L
₹624 Cr	₹135 Cr	₹285 Cr	₹483 Cr	₹202 Cr	₹222 Cr	₹275 Cr	₹421 Cr	₹1023 Cr	₹903 Cr	₹846 Cr	₹773 Cr	₹199 Cr	₹173 Cr	₹143 Cr	₹136 Cr	₹129 Cr
₹16	₹5	₹12	₹17	₹7	₹6	₹11	₹19	₹60	₹52	₹47	₹44	₹9	₹35	₹36	₹32	₹33
₹16	₹5	₹12	₹17	₹6	₹5	₹10	₹17	₹56	₹48	₹43	₹40	₹8	₹32	₹9	₹8	₹8

Cash Flow

Consolidated

Standalone

₹

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Cash & Cash Equivalent on Amalgamation / Take over / Merger

Effect of Foreign Exchange Fluctuations

Closing Cash & Cash Equivalent

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2008	Mar 2007	Mar 2006	Mar 2005	Mar 2004
-₹276 Cr	-₹161 Cr	-₹106 Cr	-₹118 Cr	-₹122 Cr	-₹77 Cr	-₹106 Cr	₹16 L	₹196 Cr	₹123 Cr	₹98 Cr	₹152 Cr	₹6 Cr	₹11 Cr	₹6 Cr	₹6 Cr	₹8 Cr
-₹6 Cr	-₹4 Cr	-₹22 Cr	-₹8 Cr	-₹1 Cr	-₹3 Cr	-₹8 Cr	-₹5 Cr	₹10 Cr	₹13 Cr	₹11 Cr	₹21 Cr	₹11 Cr	₹7 Cr	₹7 Cr	₹4 Cr	₹3 Cr
-₹18 Cr	₹10 Cr	₹7 Cr	₹11 Cr	-₹4 Cr	-₹15 Cr	-₹17 Cr	-₹33 Cr	-₹92 Cr	₹8 Cr	-₹14 Cr	₹8 Cr	-₹13 Cr	₹46 L	-₹7 Cr	-₹7 Cr	-₹6 Cr
-₹301 Cr	-₹155 Cr	-₹122 Cr	-₹115 Cr	-₹127 Cr	-₹95 Cr	-₹132 Cr	-₹38 Cr	₹113 Cr	₹144 Cr	₹94 Cr	₹181 Cr	₹5 Cr	₹18 Cr	₹7 Cr	₹3 Cr	₹5 Cr
-₹301 Cr	-₹154 Cr	-₹115 Cr	-₹116 Cr	-₹128 Cr	-₹96 Cr	-₹135 Cr	-₹53 Cr	₹70 Cr	₹109 Cr	₹67 Cr	₹143 Cr	₹4 Cr	₹16 Cr	₹6 Cr	₹2 Cr	₹4 Cr
-₹462 Cr	₹155 Cr	₹94 Cr	-₹248 Cr	-₹22 Cr	₹56 Cr	₹146 Cr	₹37 Cr	-₹61 L	-₹311 Cr	-₹39 Cr	-₹110 Cr	-₹16 Cr	-₹20 Cr	-₹9 Cr	-₹4 Cr	-₹31 Cr
₹757 Cr	-₹76 L	-₹1 Cr	₹396 Cr	₹146 Cr	₹35 Cr	₹3 Cr	₹5 Cr	-₹52 Cr	-₹30 Cr	-₹68 Cr	₹179 Cr	₹6 Cr	₹13 Cr	₹3 Cr	-₹8 Cr	₹38 Cr
-₹7 Cr	₹9 L	-₹22 Cr	₹32 Cr	-₹4 Cr	-₹5 Cr	₹14 Cr	-₹11 Cr	₹17 Cr	-₹232 Cr	-₹39 Cr	₹212 Cr	-₹7 Cr	₹8 Cr	-₹1 Cr	-₹10 Cr	₹11 Cr
₹15 Cr	₹15 Cr	₹37 Cr	₹5 Cr	₹9 Cr	₹15 Cr	₹23 L	₹18 Cr	₹9 Cr	₹241 Cr	₹280 Cr	₹68 Cr	₹10 Cr	₹1 Cr	₹3 Cr	₹12 Cr	₹71 L
₹0	₹0	₹0	₹0	₹0	₹0	₹0	-₹7 Cr	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹10 L
₹8 Cr	₹15 Cr	₹15 Cr	₹37 Cr	₹5 Cr	₹9 Cr	₹15 Cr	₹23 L	₹26 Cr	₹9 Cr	₹241 Cr	₹279 Cr	₹3 Cr	₹10 Cr	₹1 Cr	₹3 Cr	₹12 Cr

Fundamental Ratios

Consolidated

Standalone

No results found

Suven Life Sciences Share Price

261.60+0.40 (+0.15%)

+27.78% past 1 Year

Shareholding summary

Promoters

65.47%

FII

0.45%

DII

2.09%

0.08%

Others

31.91%

Promoters

FII

DII

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025
65.47%	70.08%	70.15%	67.36%	67.36%	70.27%
0.45%	0.56%	0.91%	1.07%	1.17%	0.58%
2.09%	2.92%	2.83%	1.31%	1.31%	0.01%
0.08%	0.01%	1.79%	2.08%	2.08%	0.01%
31.91%	26.43%	24.32%	28.18%	28.08%	29.13%

Bulk & block deals

Name

Graviton Research Capital Llp

Alpha Leon Enterprises Llp

Katkar Sanjay

Alpha Leon Enterprises Llp

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
11 Jan 2024	Purchase	17.40 Cr	₹121.82	14.29 L	Bulk	0.505567	NSE
11 Jan 2024	Sell	17.39 Cr	₹121.70	14.29 L	Bulk	0.505567	NSE
13 Sep 2023	Purchase	11.99 Cr	₹78.12	15.35 L	Bulk	0.543222	NSE
13 Sep 2023	Sell	12 Cr	₹78.20	15.35 L	Bulk	0.543222	NSE
23 Apr 2021	Purchase	7.03 Cr	₹109.64	6.41 L	Bulk	0.226838	NSE
23 Apr 2021	Sell	7.05 Cr	₹109.97	6.41 L	Bulk	0.226838	NSE
17 Dec 2020	Purchase	6.89 Cr	₹104.94	6.56 L	Bulk	0.232329	NSE
17 Dec 2020	Sell	6.59 Cr	₹105.08	6.27 L	Bulk	0.222061	NSE
18 Sep 2020	Purchase	3.88 Cr	₹56.27	6.89 L	Bulk	0.243802	NSE
21 Apr 2020	Sell	2.45 Cr	₹32.17	7.62 L	Bulk	0.269532	NSE

Insider trading & SAST

Client name

Jasti Property & Equity Holdings Pvt Ltd & Pacs

Jasti Property And Equity Holdings Private Limited (In Its Capacity As Sole Trustee Of Jasti Family Trust)

Jasti Property And Equity Holdings Private Limited (In Its Capacity As Sole Trustee Of The Jasti Family Trust)

Sudharani Jasti

Jasti Property & Equity Holdings Pvt Ltd & Pacs

Jasti Property And Equity Holdings Private Limited (In Its Capacity As Sole Trustee Of The Jasti Family Trust)

Reported on	Client category	Action	%Stake traded	Holding % post deal	Deal value	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
08 May 2026	Promoter	Acquisition	4.17	70.15	0	—	3.18 Cr	06 Mar 2026	Pref. Allotment	18,50,00,000	SAST	29(2)	—
10 Mar 2026	Promoter Group	Acquisition	12.046372	69.57	425.70 Cr	₹134	3.18 Cr	06 Mar 2026	Conversion of security	18,34,66,264	Insider Trading	—	Equity Shares
07 Jul 2025	Promoter Group	Acquisition	14.567903	0	425.70 Cr	₹134	3.18 Cr	03 Jul 2025	Allotment	3,17,68,764	Insider Trading	—	Warrants
29 May 2024	Promoter	Acquisition	0.7	0.7	0	—	15.26 L	28 May 2024	Transmission	15,28,535	SAST	29(2)	—
29 May 2024	Promoter & Director	Acquisition	0.69955	0.7	0	—	15.26 L	28 May 2024	Others	15,28,535	Insider Trading	—	Equity Shares
22 Nov 2022	Promoter	Acquisition	4.59	69.57	0	—	5.72 Cr	16 Nov 2022	Rights Issue	15,17,05,701	SAST	29(2)	—
30 Mar 2022	Promoter	Acquisition	4.98	64.98	0	—	1.81 Cr	28 Mar 2022	Pref. Allotment	9,44,70,000	SAST	29(2)	—
29 Mar 2022	Promoter Group	Acquisition	14.220393	64.98	147.64 Cr	₹81.57	1.81 Cr	28 Mar 2022	Conversion of security	9,44,65,000	Insider Trading	—	Equity Shares

Suven Life Sciences Share Price

Price Analysis

Share Price Live Stats

Share Market Cap & Key Ratios Overview

About

Stock Analysis (SWOT)

QVT

Peer Stocks

Suven Life Sciences Share Price

Suven Life Sciences Share Price

Financial overview

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Peer Comparison

Profit & Loss

Balance Sheet

Cash Flow

Fundamental Ratios

Suven Life Sciences Share Price

Suven Life Sciences Share Price

Oscillators

Moving averages

Suven Life Sciences Share Price

Shareholding summary

Shareholding Pattern

Bulk & block deals

Insider trading & SAST

Suven Life Sciences Share Price

Corporate Actions

Company details

Suven Life Sciences Share Price

Corporate filings & documents

Announcements

Annual reports

Concalls & investor presentations

Suven Life Sciences Share Price

News

Suven Life Sciences completes enrolment in global phase-3 Alzheimer’s trial

Suven Life Sciences Q1 FY27 loss widens despite modest revenue growth

Suven Life plans major neuroscience push and Singapore expansion by FY27

Suven Life Sciences to showcase Alzheimer’s pipeline data at AAIC 2026

Suven Life Sciences raises Rs 248.84 crores via warrant conversion, adds Singapore unit

Suven Life Sciences to present CNS pipeline, seek partnerships at BIO 2026

Suven Life Sciences reports positive topline data for key depression drug trial

Suven Life Sciences advances key CNS asset after positive Phase-1 data

Suven Life Sciences presents Samelisant clinical data at SLEEP-2026 meet

Suven Life Sciences advances global Phase 3 Alzheimer’s agitation trial successfully

Suven Life Sciences Achieves 76% Enrollment in Phase 3 Trial for Masupirdine in Alzheimer’s Agitation

Suven Life Sciences Issues 3.17 Cr Equity Shares on Warrant Conversion Raising Rs 425.70 Cr.

Suven Life Sciences Ltd Reports Q3 Consolidated Net Loss of Rs 102 Crores vs Rs 39.12 Crores YoY.

Suven Life Sciences hits full enrollment early in key Ropanicant Phase-2b trial

Suven Life Sciences reports higher Q2 consolidated net loss year-on-year for FY2025-26.

Sunil Singhania Abakkus Diversified Alpha Fund Acquires 1.32 Percent Stake in Suven Life Sciences Q2

Suven Life Sciences: Q1 Sl Net Loss 14.80 Crores Rupees Vs Loss 7.70 Crores (Yoy) || Q1 Revenue 1.90 Crores Rupees Vs 1.00 Crores (Yoy)

Suven Life Sciences - Quaterly Results

Suven Life Sciences reports Profit after tax of Rs -14.78 Crores, in the June 2025 quarter

Suven Life Sciences - Quaterly Results

Suven Life Sciences Ltd Share Price Today

Suven Life Sciences Quick Links

Other Stocks

Calculators

Brokerage Calculator

Stock Average Calculator

MTF Calculator

Margin Calculator

Span Margin Calculator